Jersey City, NJ – March 14, 2018 – WallachBeth Capital, a leading provider of institutional execution services, is acting as the sole placement agent for SmartZyme BioPharma’s Series B-1 preferred-stock round.
WallachBeth Capital has closed the first tranche of the Series B-1 financing being led by OrbiMed Advisors and Virtus Inspire Ventures.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer, if at all, was made only by means of the offering document.
About SmartZyme BioPharma, Inc.
SmartZyme BioPharma, Inc. is a medical technology company enabling a seamless leap to better performing glucose monitoring for people with diabetes. The company is accelerating the integration of SmartZyme’s next-generation glucose-sensing enzyme into continuous glucose monitoring devices. A next-generation enzyme means a device with no more hypoglycemic errors for the best safety profile; no more signal mediators for the best device performance; and no more fingersticks for the best quality of life. SmartZyme is an OrbiMed portfolio company.
About WallachBeth Capital, LLC
WallachBeth Capital offers a robust range of capital markets and investment banking services to the healthcare community, connecting corporate clients with leading institutions, creating value for both issuers and investors. The firm is a leading provider of institutional execution services, offering clients a full spectrum of solutions to help them navigate increasingly complex markets. WallachBeth’s expertise includes ETF, equity and derivative trading. Operating on a fully disclosed, agency-only basis, the firm is committed to facilitating all client needs with transparency and integrity. The firm’s website is located at www.wallachbeth.com.
For media inquiries: